colorectal cancer, Leap Therapeutics
H.C. Wainwright adjusted its stance on Leap Therapeutics (NASDAQ:LPTX), downgrading the biopharmaceutical company's stock ...
Leap Therapeutics (LPTX) lost 63% after announcing it will not run a Phase 3 trial for its lead asset sirexatamab in gastric ...
Baird downgraded Leap Therapeutics (LPTX) to Neutral from Outperform with a price target of $1.25, down from $9, after after the company ...
Leap Therapeutics, Inc.’s LPTX share price has dipped by 71.11%, which has investors questioning if this is right time to buy ...
Leap Therapeutics Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -70.45%. The profit margin, also known as the revenue ratio or gross profit ratio, ...
H.C. Wainwright downgraded Leap Therapeutics (LPTX) to Neutral from Buy without a price target after the company presented clinical data ...
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced positive initial data from Part B of the DeFianCe study ...
Leap Therapeutics is discontinuing the development of its anti-DKK1 antibody sirexatamab in gastric cancer after the drug ...
Leap Therapeutics has come crashing down to earth. The biotech axed plans to advance into phase 3 in gastric cancer on the basis of midstage data, sending its stock down 60% to below $1, but it is ...
Stocktwits on MSN2d
Leap Therapeutics Stock Plunges To Record Low After Ending Gastric Cancer Drug Trials, Retail Bets On CRC PipelineShares of Leap Therapeutics, Inc. nosedived more than 70% to an all-time low on Tuesday, making them the top loser across U.S ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback